drugset
drugset / Trial / NCT02454933

Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours

NCT02454933 ↗

Phase 3 Completed 29 enrolled AstraZeneca
RandomizedParallel-groupOpen-labelTreatment

Summary

A Phase III, Multi-Centre, Open Label, Randomized Study to Assess the Efficacy and Safety of AZD9291 in Combination with MEDI4736 versus AZD9291 Monotherapy in patients with Locally Advanced or Metastatic Epidermal Growth Factor Receptor T790M mutation-positive Non-Small Cell Lung Cancer who have received Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy

Timeline

Start
2015-07-15
Primary completion
2017-08-21
Completion
2023-06-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Durvalumab Monoclonal antibody 10 mg/kg Intravenous
Subject Osimertinib Small molecule 80 mg Oral

Indications

No indication recorded.